The Expression of Chemokine Receptors CXCR3 and CXCR4 in Predicting Postoperative Tumour Progression in Stages I-II Colon Cancer: a Retrospective Study

Overview

Journal BMJ Open

Specialty General Medicine

Date 2014 Sep 19

PMID 25232565

Citations 10

Authors

Changzheng Du

Yunfeng Yao

Weicheng Xue

Wei-Guo Zhu

Yifan Peng

Jin Gu

Affiliations

Soon will be listed here.

Abstract

Objectives: The prognostic significance of chemokine receptors in stage I/II colon cancer is unclear. We assessed the prognostic value of chemokine receptor CXCR3 and CXCR4 in stage I/II colon cancer.

Methods: 145 patients with stage I/II colon cancer who underwent curative surgery alone from 2000 to 2007 were investigated. Chemokine receptor expression was assessed by immunohistochemistry. The associations between CXCR3, CXCR4 and clinicopathological variables were analysed using the χ2 test, and the relationships between chemokine receptors and a 5-year disease-free survival were analysed by univariate and multivariate analyses.

Results: The high-expression rates of CXCR3 and CXCR4 were 17.9% (26/145) and 38.6% (56/145), respectively. There were no significant associations between the expressions of CXCR3, CXCR4 and clinicopathological factors including gender, age, tumour location, histological differentiation, pathological stage, lymphovascular invasion and pretreatment serum carcinoembryonic antigen (CEA). The 5-year disease-free survival was not significantly different between low-expression groups and high-expression groups of CXCR3 and CXCR4. Multivariate analysis revealed that serum CEA and a number of retrieved lymph nodes, rather than chemokine receptors, were independent prognosticators.

Conclusions: CXCR3 and CXCR4 are not independent prognosticators for stage I/II colon cancer after curative surgery.

Citing Articles

Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative management.

Alnakli A, Mohamedali A, Heng B, Chan C, Shin J, Solomon M BJC Rep. 2024; 2(1):13.

PMID: 39516345 PMC: 11523985. DOI: 10.1038/s44276-024-00043-z.

TNF-α augments CXCL10/CXCR3 axis activity to induce Epithelial-Mesenchymal Transition in colon cancer cell.

Wang Z, Ao X, Shen Z, Ao L, Wu X, Pu C Int J Biol Sci. 2021; 17(11):2683-2702.

PMID: 34345201 PMC: 8326125. DOI: 10.7150/ijbs.61350.

Prognostic Significance of CXCR4 in Colorectal Cancer: An Updated Meta-Analysis and Critical Appraisal.

Ottaiano A, Santorsola M, Prete P, Perri F, Scala S, Caraglia M Cancers (Basel). 2021; 13(13).

PMID: 34209026 PMC: 8269109. DOI: 10.3390/cancers13133284.

Expression of E-cadherin and specific CXCR3 isoforms impact each other in prostate cancer.

Ma B, Khazali A, Shao H, Jiang Y, Wells A Cell Commun Signal. 2019; 17(1):164.

PMID: 31831069 PMC: 6909607. DOI: 10.1186/s12964-019-0489-1.

CXCR3 is a prognostic marker and a potential target for patients with solid tumors: a meta-analysis.

Zhang Y, Xu L, Peng M Onco Targets Ther. 2018; 11:1045-1054.

PMID: 29520155 PMC: 5833761. DOI: 10.2147/OTT.S157421.

References

Wolpin B, Meyerhardt J, Mamon H, Mayer R . Adjuvant treatment of colorectal cancer. CA Cancer J Clin. 2007; 57(3):168-85. DOI: 10.3322/canjclin.57.3.168. View

Wu Z, Han X, Yan J, Pan Y, Gong J, Di J . The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma. Biomed Pharmacother. 2012; 66(5):373-7. DOI: 10.1016/j.biopha.2011.12.003. View

Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K . ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012; 23(10):2479-2516. DOI: 10.1093/annonc/mds236. View

Koebrugge B, Vogelaar F, Lips D, Pruijt J, van der Linden J, Ernst M . The number of high-risk factors is related to outcome in stage II colonic cancer patients. Eur J Surg Oncol. 2011; 37(11):964-70. DOI: 10.1016/j.ejso.2011.08.135. View

Vandercappellen J, Van Damme J, Struyf S . The role of CXC chemokines and their receptors in cancer. Cancer Lett. 2008; 267(2):226-44. DOI: 10.1016/j.canlet.2008.04.050. View

Cambien B, Karimdjee B, Richard-Fiardo P, Bziouech H, Barthel R, Millet M . Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer. 2009; 100(11):1755-64. PMC: 2695685. DOI: 10.1038/sj.bjc.6605078. View

OConnor E, Greenblatt D, Loconte N, Gangnon R, Liou J, Heise C . Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011; 29(25):3381-8. PMC: 3164243. DOI: 10.1200/JCO.2010.34.3426. View

Balkwill F . The chemokine system and cancer. J Pathol. 2011; 226(2):148-57. DOI: 10.1002/path.3029. View

Frick V, Rubie C, Ghadjar P, Faust S, Wagner M, Graber S . Changes in CXCL12/CXCR4-chemokine expression during onset of colorectal malignancies. Tumour Biol. 2010; 32(1):189-96. DOI: 10.1007/s13277-010-0112-y. View

10.

Kawada K, Hosogi H, Sonoshita M, Sakashita H, Manabe T, Shimahara Y . Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene. 2007; 26(32):4679-88. DOI: 10.1038/sj.onc.1210267. View

11.

Kim J, Takeuchi H, Lam S, Turner R, Wang H, Kuo C . Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol. 2005; 23(12):2744-53. DOI: 10.1200/JCO.2005.07.078. View

12.

Fukunaga S, Maeda K, Noda E, Inoue T, Wada K, Hirakawa K . Association between expression of vascular endothelial growth factor C, chemokine receptor CXCR4 and lymph node metastasis in colorectal cancer. Oncology. 2007; 71(3-4):204-11. DOI: 10.1159/000106070. View

13.

Benson 3rd A, Schrag D, Somerfield M, Cohen A, Figueredo A, Flynn P . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22(16):3408-19. DOI: 10.1200/JCO.2004.05.063. View

14.

Sakai N, Yoshidome H, Shida T, Kimura F, Shimizu H, Ohtsuka M . CXCR4/CXCL12 expression profile is associated with tumor microenvironment and clinical outcome of liver metastases of colorectal cancer. Clin Exp Metastasis. 2011; 29(2):101-10. DOI: 10.1007/s10585-011-9433-5. View

15.

Murakami T, Kawada K, Iwamoto M, Akagami M, Hida K, Nakanishi Y . The role of CXCR3 and CXCR4 in colorectal cancer metastasis. Int J Cancer. 2012; 132(2):276-87. DOI: 10.1002/ijc.27670. View

16.

Ottaiano A, Franco R, Aiello Talamanca A, Liguori G, Tatangelo F, Delrio P . Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. Clin Cancer Res. 2006; 12(9):2795-803. DOI: 10.1158/1078-0432.CCR-05-2142. View

17.

Kim J, Mori T, Chen S, Amersi F, Martinez S, Kuo C . Chemokine receptor CXCR4 expression in patients with melanoma and colorectal cancer liver metastases and the association with disease outcome. Ann Surg. 2006; 244(1):113-20. PMC: 1570598. DOI: 10.1097/01.sla.0000217690.65909.9c. View

18.

Storli K, Sondenaa K, Bukholm I, Nesvik I, Bru T, Furnes B . Overall survival after resection for colon cancer in a national cohort study was adversely affected by TNM stage, lymph node ratio, gender, and old age. Int J Colorectal Dis. 2011; 26(10):1299-307. PMC: 3176397. DOI: 10.1007/s00384-011-1244-2. View

19.

Zhang N, Li J, Li Y, Zhang X, Liao W, Zhang J . Co-expression of CXCR4 and CD133 proteins is associated with poor prognosis in stage II-III colon cancer patients. Exp Ther Med. 2012; 3(6):973-982. PMC: 3438782. DOI: 10.3892/etm.2012.527. View

20.

Schimanski C, Schwald S, Simiantonaki N, Jayasinghe C, Gonner U, Wilsberg V . Effect of chemokine receptors CXCR4 and CCR7 on the metastatic behavior of human colorectal cancer. Clin Cancer Res. 2005; 11(5):1743-50. DOI: 10.1158/1078-0432.CCR-04-1195. View